"10.1371_journal.pone.0093441","plos one","2014-04-15T00:00:00Z","Jonathan W Kotula; Jinpeng Sun; Margie Li; Elizabeth D Pratico; Mark P Fereshteh; Douglas P Ahrens; Bruce A Sullenger; Jeffrey J Kovacs","Departments of Surgery and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, United States of America; Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina, United States of America; b3 bio, Inc. Research Triangle Park, North Carolina, United States of America","Conceived and designed the experiments: JWK JS BAS JJK. Performed the experiments: JWK JS ML EDP MPF DPA JJK. Analyzed the data: JWK JS ML EDP MPF DPA JJK. Contributed reagents/materials/analysis tools: JWK JS ML EDP MPF DPA JJK. Wrote the paper: JWK JS JJK.","The authors have the following conflicts: JWK, JS, BAS, and JJK have a patent application submitted based on work related to this manuscript. b3 bio, Inc. was a small biotechnology company located at 6 Davis Dr. Research Triangle Park, N.C. 27709. Dr. Sullenger was a founder and member of the Scientific Advisory Board for b3 bio, while Dr. Kovacs and Mr. Ahrens were Sr. Research Scientists at the company. The company closed on December 3rd 2012 which consequently ended Dr. Kovacs’ and Mr. Ahrens’ employment. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. Drs. Kovacs, Sullenger, Kotula, Fereshteh and Sun are co-inventors on international patent application WO/2011/133211 A2 Compositions for Binding β-arrestin, and Their Use to Modulate β-arrestin Activity published October 27th 2011, however, that patent application has been abandoned. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2014","04","Jonathan W Kotula","JWK",8,TRUE,4,7,7,3,TRUE,TRUE,FALSE,0,NA,FALSE
